Gilead: Q2 Earnings Snapshot

63
6
Favorite

Gilead: Q2 Earnings Snapshot

sfgate2021-07-30

FOSTER CITY, Calif. (AP) _ Gilead Sciences Inc. (GILD) on Thursday reported second-quarter net income of $1.52 billion, after reporting a loss in the same period a year earlier.

On a per-share basis, the Foster City, California-based company said it had net income of $1.21. Earnings, adjusted for non-recurring costs, were $1.87 per share.

The results beat Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $1.76 per share.

The HIV and hepatitis C drugmaker posted revenue of $6.22 billion in the period, also topping Street forecasts. Six analysts surveyed by Zacks expected $6.15 billion.

Gilead expects full-year earnings in the range of $6.90 to $7.25 per share.

Gilead shares have climbed 20% since the beginning of the year, while the S&P's 500 index has increased 18%. In the final minutes of trading on Thursday, shares hit $69.81, a decrease of slightly more than 4% in the last 12 months.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（6）

mseokt
·2021-07-30
Yess ?
Reply
Like
Report
Leehui1984
·2021-07-30
Good
Reply
Like
Report
HappyWolf
·2021-07-30
[Cool] [Cool]
Reply
1
Report
NatYong
·2021-07-30
In the final minutes of trading on Thursday, shares hit $69.81, a decrease of slightly more than 4% in the last 12 months.
Reply
1
Report
Haw75
·2021-07-30
Like latest
Reply
2
Report
KaiQING
·2021-07-30
,
Reply
Like
Report

Most Discussed

7x24

All

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1165365936?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-07-30 09:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165365936","market":"us","top_or_hot":-1,"title":"Gilead: Q2 Earnings Snapshot","media":"sfgate","content":"<p>FOSTER CITY, Calif. (AP) _ Gilead Sciences Inc. (GILD) on Thursday reported second-quarter net income of $1.52 billion, after reporting a loss in the same period a year earlier.</p>\n<p>On a per-share basis, the Foster City, California-based company said it had net income of $1.21. Earnings, adjusted for non-recurring costs, were $1.87 per share.</p>\n<p>The results beat Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $1.76 per share.</p>\n<p>The HIV and hepatitis C drugmaker posted revenue of $6.22 billion in the period, also topping Street forecasts. Six analysts surveyed by Zacks expected $6.15 billion.</p>\n<p>Gilead expects full-year earnings in the range of $6.90 to $7.25 per share.</p>\n<p>Gilead shares have climbed 20% since the beginning of the year, while the S&amp;P's 500 index has increased 18%. In the final minutes of trading on Thursday, shares hit $69.81, a decrease of slightly more than 4% in the last 12 months.</p>","source":"lsy1627607889170","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead: Q2 Earnings Snapshot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead: Q2 Earnings Snapshot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 09:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.sfgate.com/business/article/Gilead-Q2-Earnings-Snapshot-16350010.php><strong>sfgate</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>FOSTER CITY, Calif. (AP) _ Gilead Sciences Inc. (GILD) on Thursday reported second-quarter net income of $1.52 billion, after reporting a loss in the same period a year earlier.\nOn a per-share basis, ...</p>\n\n<a href=\"https://www.sfgate.com/business/article/Gilead-Q2-Earnings-Snapshot-16350010.php\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GILD","symbol_name":"吉利德科学","start_time":0,"source_url":"https://www.sfgate.com/business/article/Gilead-Q2-Earnings-Snapshot-16350010.php","article_id":"1165365936","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165365936","pubTimestamp":1627607851,"columns":[],"sourceInfo":{"source_id":"lsy1627607889170","name":"sfgate"},"weMediaInfo":null,"summary":"FOSTER CITY, Calif. (AP) _ Gilead Sciences Inc. (GILD) on Thursday reported second-quarter net incom","collect":0,"end_time":0,"defaultTopTitle":"sfgate.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"GILD":"吉利德科学"},"translate_title":"基列:Q2收益快照","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":0.9},"content_text":"FOSTER CITY, Calif. (AP) _ Gilead Sciences Inc. (GILD) on Thursday reported second-quarter net income of $1.52 billion, after reporting a loss in the same period a year earlier.\nOn a per-share basis, the Foster City, California-based company said it had net income of $1.21. Earnings, adjusted for non-recurring costs, were $1.87 per share.\nThe results beat Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $1.76 per share.\nThe HIV and hepatitis C drugmaker posted revenue of $6.22 billion in the period, also topping Street forecasts. Six analysts surveyed by Zacks expected $6.15 billion.\nGilead expects full-year earnings in the range of $6.90 to $7.25 per share.\nGilead shares have climbed 20% since the beginning of the year, while the S&P's 500 index has increased 18%. In the final minutes of trading on Thursday, shares hit $69.81, a decrease of slightly more than 4% in the last 12 months.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":808750338,"gmtCreate":1627611911424,"gmtModify":1703493350109,"author":{"id":"3577447162748311","authorId":"3577447162748311","name":"mseokt","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3577447162748311","authorIdStr":"3577447162748311"},"htmlText":"Yess ?&nbsp;","listText":"Yess ?&nbsp;","text":"Yess ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/808750338","repostId":1165365936,"repostType":4,"repost":{"id":"1165365936","kind":"news","pubTimestamp":1627607851,"share":"https://ttm.financial/m/news/1165365936?lang=&edition=fundamental","pubTime":"2021-07-30 09:17","market":"us","language":"en","title":"Gilead: Q2 Earnings Snapshot","url":"https://stock-news.laohu8.com/highlight/detail?id=1165365936","media":"sfgate","summary":"FOSTER CITY, Calif. (AP) _ Gilead Sciences Inc. (GILD) on Thursday reported second-quarter net incom","content":"<p>FOSTER CITY, Calif. (AP) _ Gilead Sciences Inc. (GILD) on Thursday reported second-quarter net income of $1.52 billion, after reporting a loss in the same period a year earlier.</p>\n<p>On a per-share basis, the Foster City, California-based company said it had net income of $1.21. Earnings, adjusted for non-recurring costs, were $1.87 per share.</p>\n<p>The results beat Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $1.76 per share.</p>\n<p>The HIV and hepatitis C drugmaker posted revenue of $6.22 billion in the period, also topping Street forecasts. Six analysts surveyed by Zacks expected $6.15 billion.</p>\n<p>Gilead expects full-year earnings in the range of $6.90 to $7.25 per share.</p>\n<p>Gilead shares have climbed 20% since the beginning of the year, while the S&amp;P's 500 index has increased 18%. In the final minutes of trading on Thursday, shares hit $69.81, a decrease of slightly more than 4% in the last 12 months.</p>","source":"lsy1627607889170","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead: Q2 Earnings Snapshot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead: Q2 Earnings Snapshot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 09:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.sfgate.com/business/article/Gilead-Q2-Earnings-Snapshot-16350010.php><strong>sfgate</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>FOSTER CITY, Calif. (AP) _ Gilead Sciences Inc. (GILD) on Thursday reported second-quarter net income of $1.52 billion, after reporting a loss in the same period a year earlier.\nOn a per-share basis, ...</p>\n\n<a href=\"https://www.sfgate.com/business/article/Gilead-Q2-Earnings-Snapshot-16350010.php\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学"},"source_url":"https://www.sfgate.com/business/article/Gilead-Q2-Earnings-Snapshot-16350010.php","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165365936","content_text":"FOSTER CITY, Calif. (AP) _ Gilead Sciences Inc. (GILD) on Thursday reported second-quarter net income of $1.52 billion, after reporting a loss in the same period a year earlier.\nOn a per-share basis, the Foster City, California-based company said it had net income of $1.21. Earnings, adjusted for non-recurring costs, were $1.87 per share.\nThe results beat Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $1.76 per share.\nThe HIV and hepatitis C drugmaker posted revenue of $6.22 billion in the period, also topping Street forecasts. Six analysts surveyed by Zacks expected $6.15 billion.\nGilead expects full-year earnings in the range of $6.90 to $7.25 per share.\nGilead shares have climbed 20% since the beginning of the year, while the S&P's 500 index has increased 18%. In the final minutes of trading on Thursday, shares hit $69.81, a decrease of slightly more than 4% in the last 12 months.","news_type":1,"symbols_score_info":{"GILD":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":808726927,"gmtCreate":1627611578769,"gmtModify":1703493343303,"author":{"id":"4089182849487330","authorId":"4089182849487330","name":"Leehui1984","avatar":"https://static.tigerbbs.com/38381321356ff7f33e4c88f960c1a24c","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"4089182849487330","authorIdStr":"4089182849487330"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/808726927","repostId":1165365936,"repostType":4,"repost":{"id":"1165365936","kind":"news","pubTimestamp":1627607851,"share":"https://ttm.financial/m/news/1165365936?lang=&edition=fundamental","pubTime":"2021-07-30 09:17","market":"us","language":"en","title":"Gilead: Q2 Earnings Snapshot","url":"https://stock-news.laohu8.com/highlight/detail?id=1165365936","media":"sfgate","summary":"FOSTER CITY, Calif. (AP) _ Gilead Sciences Inc. (GILD) on Thursday reported second-quarter net incom","content":"<p>FOSTER CITY, Calif. (AP) _ Gilead Sciences Inc. (GILD) on Thursday reported second-quarter net income of $1.52 billion, after reporting a loss in the same period a year earlier.</p>\n<p>On a per-share basis, the Foster City, California-based company said it had net income of $1.21. Earnings, adjusted for non-recurring costs, were $1.87 per share.</p>\n<p>The results beat Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $1.76 per share.</p>\n<p>The HIV and hepatitis C drugmaker posted revenue of $6.22 billion in the period, also topping Street forecasts. Six analysts surveyed by Zacks expected $6.15 billion.</p>\n<p>Gilead expects full-year earnings in the range of $6.90 to $7.25 per share.</p>\n<p>Gilead shares have climbed 20% since the beginning of the year, while the S&amp;P's 500 index has increased 18%. In the final minutes of trading on Thursday, shares hit $69.81, a decrease of slightly more than 4% in the last 12 months.</p>","source":"lsy1627607889170","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead: Q2 Earnings Snapshot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead: Q2 Earnings Snapshot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 09:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.sfgate.com/business/article/Gilead-Q2-Earnings-Snapshot-16350010.php><strong>sfgate</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>FOSTER CITY, Calif. (AP) _ Gilead Sciences Inc. (GILD) on Thursday reported second-quarter net income of $1.52 billion, after reporting a loss in the same period a year earlier.\nOn a per-share basis, ...</p>\n\n<a href=\"https://www.sfgate.com/business/article/Gilead-Q2-Earnings-Snapshot-16350010.php\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学"},"source_url":"https://www.sfgate.com/business/article/Gilead-Q2-Earnings-Snapshot-16350010.php","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165365936","content_text":"FOSTER CITY, Calif. (AP) _ Gilead Sciences Inc. (GILD) on Thursday reported second-quarter net income of $1.52 billion, after reporting a loss in the same period a year earlier.\nOn a per-share basis, the Foster City, California-based company said it had net income of $1.21. Earnings, adjusted for non-recurring costs, were $1.87 per share.\nThe results beat Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $1.76 per share.\nThe HIV and hepatitis C drugmaker posted revenue of $6.22 billion in the period, also topping Street forecasts. Six analysts surveyed by Zacks expected $6.15 billion.\nGilead expects full-year earnings in the range of $6.90 to $7.25 per share.\nGilead shares have climbed 20% since the beginning of the year, while the S&P's 500 index has increased 18%. In the final minutes of trading on Thursday, shares hit $69.81, a decrease of slightly more than 4% in the last 12 months.","news_type":1,"symbols_score_info":{"GILD":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":808729882,"gmtCreate":1627611405246,"gmtModify":1703493338464,"author":{"id":"3581932792448241","authorId":"3581932792448241","name":"HappyWolf","avatar":"https://static.itradeup.com/news/e4fffae39efcb1f9b6eac5b65984d673","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3581932792448241","authorIdStr":"3581932792448241"},"htmlText":"[Cool]&nbsp;[Cool]&nbsp;","listText":"[Cool]&nbsp;[Cool]&nbsp;","text":"[Cool] [Cool]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/808729882","repostId":1165365936,"repostType":4,"repost":{"id":"1165365936","kind":"news","pubTimestamp":1627607851,"share":"https://ttm.financial/m/news/1165365936?lang=&edition=fundamental","pubTime":"2021-07-30 09:17","market":"us","language":"en","title":"Gilead: Q2 Earnings Snapshot","url":"https://stock-news.laohu8.com/highlight/detail?id=1165365936","media":"sfgate","summary":"FOSTER CITY, Calif. (AP) _ Gilead Sciences Inc. (GILD) on Thursday reported second-quarter net incom","content":"<p>FOSTER CITY, Calif. (AP) _ Gilead Sciences Inc. (GILD) on Thursday reported second-quarter net income of $1.52 billion, after reporting a loss in the same period a year earlier.</p>\n<p>On a per-share basis, the Foster City, California-based company said it had net income of $1.21. Earnings, adjusted for non-recurring costs, were $1.87 per share.</p>\n<p>The results beat Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $1.76 per share.</p>\n<p>The HIV and hepatitis C drugmaker posted revenue of $6.22 billion in the period, also topping Street forecasts. Six analysts surveyed by Zacks expected $6.15 billion.</p>\n<p>Gilead expects full-year earnings in the range of $6.90 to $7.25 per share.</p>\n<p>Gilead shares have climbed 20% since the beginning of the year, while the S&amp;P's 500 index has increased 18%. In the final minutes of trading on Thursday, shares hit $69.81, a decrease of slightly more than 4% in the last 12 months.</p>","source":"lsy1627607889170","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead: Q2 Earnings Snapshot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead: Q2 Earnings Snapshot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 09:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.sfgate.com/business/article/Gilead-Q2-Earnings-Snapshot-16350010.php><strong>sfgate</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>FOSTER CITY, Calif. (AP) _ Gilead Sciences Inc. (GILD) on Thursday reported second-quarter net income of $1.52 billion, after reporting a loss in the same period a year earlier.\nOn a per-share basis, ...</p>\n\n<a href=\"https://www.sfgate.com/business/article/Gilead-Q2-Earnings-Snapshot-16350010.php\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学"},"source_url":"https://www.sfgate.com/business/article/Gilead-Q2-Earnings-Snapshot-16350010.php","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165365936","content_text":"FOSTER CITY, Calif. (AP) _ Gilead Sciences Inc. (GILD) on Thursday reported second-quarter net income of $1.52 billion, after reporting a loss in the same period a year earlier.\nOn a per-share basis, the Foster City, California-based company said it had net income of $1.21. Earnings, adjusted for non-recurring costs, were $1.87 per share.\nThe results beat Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $1.76 per share.\nThe HIV and hepatitis C drugmaker posted revenue of $6.22 billion in the period, also topping Street forecasts. Six analysts surveyed by Zacks expected $6.15 billion.\nGilead expects full-year earnings in the range of $6.90 to $7.25 per share.\nGilead shares have climbed 20% since the beginning of the year, while the S&P's 500 index has increased 18%. In the final minutes of trading on Thursday, shares hit $69.81, a decrease of slightly more than 4% in the last 12 months.","news_type":1,"symbols_score_info":{"GILD":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":808782512,"gmtCreate":1627610703536,"gmtModify":1703493318288,"author":{"id":"3580207321438450","authorId":"3580207321438450","name":"NatYong","avatar":"https://static.tigerbbs.com/62b1fa39b2974271d1c06e208f7b3571","vip":1,"crmLevel":12,"crmLevelSwitch":0,"idStr":"3580207321438450","authorIdStr":"3580207321438450"},"htmlText":"In the final minutes of trading on Thursday, shares hit $69.81, a decrease of slightly more than 4% in the last 12 months.","listText":"In the final minutes of trading on Thursday, shares hit $69.81, a decrease of slightly more than 4% in the last 12 months.","text":"In the final minutes of trading on Thursday, shares hit $69.81, a decrease of slightly more than 4% in the last 12 months.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/808782512","repostId":1165365936,"repostType":4,"repost":{"id":"1165365936","kind":"news","pubTimestamp":1627607851,"share":"https://ttm.financial/m/news/1165365936?lang=&edition=fundamental","pubTime":"2021-07-30 09:17","market":"us","language":"en","title":"Gilead: Q2 Earnings Snapshot","url":"https://stock-news.laohu8.com/highlight/detail?id=1165365936","media":"sfgate","summary":"FOSTER CITY, Calif. (AP) _ Gilead Sciences Inc. (GILD) on Thursday reported second-quarter net incom","content":"<p>FOSTER CITY, Calif. (AP) _ Gilead Sciences Inc. (GILD) on Thursday reported second-quarter net income of $1.52 billion, after reporting a loss in the same period a year earlier.</p>\n<p>On a per-share basis, the Foster City, California-based company said it had net income of $1.21. Earnings, adjusted for non-recurring costs, were $1.87 per share.</p>\n<p>The results beat Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $1.76 per share.</p>\n<p>The HIV and hepatitis C drugmaker posted revenue of $6.22 billion in the period, also topping Street forecasts. Six analysts surveyed by Zacks expected $6.15 billion.</p>\n<p>Gilead expects full-year earnings in the range of $6.90 to $7.25 per share.</p>\n<p>Gilead shares have climbed 20% since the beginning of the year, while the S&amp;P's 500 index has increased 18%. In the final minutes of trading on Thursday, shares hit $69.81, a decrease of slightly more than 4% in the last 12 months.</p>","source":"lsy1627607889170","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead: Q2 Earnings Snapshot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead: Q2 Earnings Snapshot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 09:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.sfgate.com/business/article/Gilead-Q2-Earnings-Snapshot-16350010.php><strong>sfgate</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>FOSTER CITY, Calif. (AP) _ Gilead Sciences Inc. (GILD) on Thursday reported second-quarter net income of $1.52 billion, after reporting a loss in the same period a year earlier.\nOn a per-share basis, ...</p>\n\n<a href=\"https://www.sfgate.com/business/article/Gilead-Q2-Earnings-Snapshot-16350010.php\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学"},"source_url":"https://www.sfgate.com/business/article/Gilead-Q2-Earnings-Snapshot-16350010.php","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165365936","content_text":"FOSTER CITY, Calif. (AP) _ Gilead Sciences Inc. (GILD) on Thursday reported second-quarter net income of $1.52 billion, after reporting a loss in the same period a year earlier.\nOn a per-share basis, the Foster City, California-based company said it had net income of $1.21. Earnings, adjusted for non-recurring costs, were $1.87 per share.\nThe results beat Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $1.76 per share.\nThe HIV and hepatitis C drugmaker posted revenue of $6.22 billion in the period, also topping Street forecasts. Six analysts surveyed by Zacks expected $6.15 billion.\nGilead expects full-year earnings in the range of $6.90 to $7.25 per share.\nGilead shares have climbed 20% since the beginning of the year, while the S&P's 500 index has increased 18%. In the final minutes of trading on Thursday, shares hit $69.81, a decrease of slightly more than 4% in the last 12 months.","news_type":1,"symbols_score_info":{"GILD":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":808472233,"gmtCreate":1627608375922,"gmtModify":1703493246071,"author":{"id":"3580379447244817","authorId":"3580379447244817","name":"Haw75","avatar":"https://static.tigerbbs.com/b8a435feb2331b895463eca3c73cdb3f","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3580379447244817","authorIdStr":"3580379447244817"},"htmlText":"Like latest&nbsp;","listText":"Like latest&nbsp;","text":"Like latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/808472233","repostId":1165365936,"repostType":4,"repost":{"id":"1165365936","kind":"news","pubTimestamp":1627607851,"share":"https://ttm.financial/m/news/1165365936?lang=&edition=fundamental","pubTime":"2021-07-30 09:17","market":"us","language":"en","title":"Gilead: Q2 Earnings Snapshot","url":"https://stock-news.laohu8.com/highlight/detail?id=1165365936","media":"sfgate","summary":"FOSTER CITY, Calif. (AP) _ Gilead Sciences Inc. (GILD) on Thursday reported second-quarter net incom","content":"<p>FOSTER CITY, Calif. (AP) _ Gilead Sciences Inc. (GILD) on Thursday reported second-quarter net income of $1.52 billion, after reporting a loss in the same period a year earlier.</p>\n<p>On a per-share basis, the Foster City, California-based company said it had net income of $1.21. Earnings, adjusted for non-recurring costs, were $1.87 per share.</p>\n<p>The results beat Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $1.76 per share.</p>\n<p>The HIV and hepatitis C drugmaker posted revenue of $6.22 billion in the period, also topping Street forecasts. Six analysts surveyed by Zacks expected $6.15 billion.</p>\n<p>Gilead expects full-year earnings in the range of $6.90 to $7.25 per share.</p>\n<p>Gilead shares have climbed 20% since the beginning of the year, while the S&amp;P's 500 index has increased 18%. In the final minutes of trading on Thursday, shares hit $69.81, a decrease of slightly more than 4% in the last 12 months.</p>","source":"lsy1627607889170","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead: Q2 Earnings Snapshot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead: Q2 Earnings Snapshot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 09:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.sfgate.com/business/article/Gilead-Q2-Earnings-Snapshot-16350010.php><strong>sfgate</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>FOSTER CITY, Calif. (AP) _ Gilead Sciences Inc. (GILD) on Thursday reported second-quarter net income of $1.52 billion, after reporting a loss in the same period a year earlier.\nOn a per-share basis, ...</p>\n\n<a href=\"https://www.sfgate.com/business/article/Gilead-Q2-Earnings-Snapshot-16350010.php\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学"},"source_url":"https://www.sfgate.com/business/article/Gilead-Q2-Earnings-Snapshot-16350010.php","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165365936","content_text":"FOSTER CITY, Calif. (AP) _ Gilead Sciences Inc. (GILD) on Thursday reported second-quarter net income of $1.52 billion, after reporting a loss in the same period a year earlier.\nOn a per-share basis, the Foster City, California-based company said it had net income of $1.21. Earnings, adjusted for non-recurring costs, were $1.87 per share.\nThe results beat Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $1.76 per share.\nThe HIV and hepatitis C drugmaker posted revenue of $6.22 billion in the period, also topping Street forecasts. Six analysts surveyed by Zacks expected $6.15 billion.\nGilead expects full-year earnings in the range of $6.90 to $7.25 per share.\nGilead shares have climbed 20% since the beginning of the year, while the S&P's 500 index has increased 18%. In the final minutes of trading on Thursday, shares hit $69.81, a decrease of slightly more than 4% in the last 12 months.","news_type":1,"symbols_score_info":{"GILD":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":808442518,"gmtCreate":1627607987934,"gmtModify":1703493231236,"author":{"id":"4090412213909750","authorId":"4090412213909750","name":"KaiQING","avatar":"https://static.tigerbbs.com/811a0407a50f920860fc236cb86b5544","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"4090412213909750","authorIdStr":"4090412213909750"},"htmlText":",","listText":",","text":",","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/808442518","repostId":1165365936,"repostType":4,"repost":{"id":"1165365936","kind":"news","pubTimestamp":1627607851,"share":"https://ttm.financial/m/news/1165365936?lang=&edition=fundamental","pubTime":"2021-07-30 09:17","market":"us","language":"en","title":"Gilead: Q2 Earnings Snapshot","url":"https://stock-news.laohu8.com/highlight/detail?id=1165365936","media":"sfgate","summary":"FOSTER CITY, Calif. (AP) _ Gilead Sciences Inc. (GILD) on Thursday reported second-quarter net incom","content":"<p>FOSTER CITY, Calif. (AP) _ Gilead Sciences Inc. (GILD) on Thursday reported second-quarter net income of $1.52 billion, after reporting a loss in the same period a year earlier.</p>\n<p>On a per-share basis, the Foster City, California-based company said it had net income of $1.21. Earnings, adjusted for non-recurring costs, were $1.87 per share.</p>\n<p>The results beat Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $1.76 per share.</p>\n<p>The HIV and hepatitis C drugmaker posted revenue of $6.22 billion in the period, also topping Street forecasts. Six analysts surveyed by Zacks expected $6.15 billion.</p>\n<p>Gilead expects full-year earnings in the range of $6.90 to $7.25 per share.</p>\n<p>Gilead shares have climbed 20% since the beginning of the year, while the S&amp;P's 500 index has increased 18%. In the final minutes of trading on Thursday, shares hit $69.81, a decrease of slightly more than 4% in the last 12 months.</p>","source":"lsy1627607889170","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead: Q2 Earnings Snapshot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead: Q2 Earnings Snapshot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 09:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.sfgate.com/business/article/Gilead-Q2-Earnings-Snapshot-16350010.php><strong>sfgate</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>FOSTER CITY, Calif. (AP) _ Gilead Sciences Inc. (GILD) on Thursday reported second-quarter net income of $1.52 billion, after reporting a loss in the same period a year earlier.\nOn a per-share basis, ...</p>\n\n<a href=\"https://www.sfgate.com/business/article/Gilead-Q2-Earnings-Snapshot-16350010.php\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学"},"source_url":"https://www.sfgate.com/business/article/Gilead-Q2-Earnings-Snapshot-16350010.php","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165365936","content_text":"FOSTER CITY, Calif. (AP) _ Gilead Sciences Inc. (GILD) on Thursday reported second-quarter net income of $1.52 billion, after reporting a loss in the same period a year earlier.\nOn a per-share basis, the Foster City, California-based company said it had net income of $1.21. Earnings, adjusted for non-recurring costs, were $1.87 per share.\nThe results beat Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $1.76 per share.\nThe HIV and hepatitis C drugmaker posted revenue of $6.22 billion in the period, also topping Street forecasts. Six analysts surveyed by Zacks expected $6.15 billion.\nGilead expects full-year earnings in the range of $6.90 to $7.25 per share.\nGilead shares have climbed 20% since the beginning of the year, while the S&P's 500 index has increased 18%. In the final minutes of trading on Thursday, shares hit $69.81, a decrease of slightly more than 4% in the last 12 months.","news_type":1,"symbols_score_info":{"GILD":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":63,"commentSize":6,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}